Faster drug recalls, safer patients: How diverse corporate boards protect public health and stock prices

When unexpected medical complications arise from prescription drugs, every additional day that a harmful product remains on store shelves puts human lives at risk. Yet corporate leaders often hesitate to pull a profitable drug from the market due to financial concerns. New research from the Alberta School of Business reveals that the key to speeding up life-saving drug recalls may lie in who sits at the boardroom table.

The study led by researcher Minjae Kim at the University of Alberta’s School of Business demonstrates that pharmaceutical companies with a higher proportion of female and foreign directors respond significantly faster to adverse drug event reports than companies with homogeneous boards.

Diverse perspectives combat groupthink

By analyzing more than 147,000 drug-firm observations and official U.S. Food and Drug Administration (FDA) safety reports, researchers tracked how corporate board composition directly impacts the speed of drug recalls.

The findings were striking: firms with high foreign director representation were 156 per cent more likely to issue a recall at any given point following safety warnings, while those with high female director representation were nearly 300 per cent more likely to act promptly.

"When a health crisis hits, corporate boards face immense pressure to balance financial fallout against public safety," says Kim.

"Foreign and female directors bring varied regulatory experiences, heightened ethical sensitivity, and fresh risk perspectives that help break through groupthink and prioritize patient welfare when time is critical."

The paper notes that foreign directors often bring familiarity with global regulatory standards and a sharp awareness of multi-market reputational risks, while female directors regularly foster collaborative decision-making and strong ethical oversight.

The financial penalty for delay

Beyond protecting patients, prompt decision-making also shields corporate value.

The researchers found that when companies with less diverse boards delayed recalls, the financial market punished them severely. Firms with low foreign board representation suffered an average 18.4 per cent drop in market-adjusted stock returns over the 60 days following a recall decision compared to their diverse peers.

"Delaying a recall doesn't protect shareholder value — it destroys it," says Kim.

"Investors recognize when a company is dragging its feet on safety. Board diversity isn't just a moral imperative or a social checkbox; it is a critical governance tool that acts as an early warning system and protects a firm's long-term financial health."

Key takeaways

• Faster safety response: Pharmaceutical firms with higher proportions of female and foreign board directors issue drug recalls significantly faster following safety reports than less diverse boards.
• Stronger hazard ratios: Companies with high female director representation are nearly 300 per cent more likely to initiate a prompt recall at any given time, while those with high foreign director representation are 156 per cent more likely to act quickly.
• Market penalties for hesitation: Firms that delay recall decisions due to a lack of foreign board diversity experience severe stock penalties, losing an average of 18.4 per cent in market-adjusted returns over 60 days.
• Governance as risk prevention: Demographic diversity introduces broader risk frameworks and ethical oversight, helping firms mitigate reputational damage and protect public health during high-stakes corporate crises.

Read Kim's full study in Finance Research Letters at DOI:10.1016/j.frl.2025.107387 .

U of A research. Real-World impact.

From cancer research discoveries to improving mental health care, learn how the U of A is striving to achieve the UN's goal of a healthier, more equitable world.

See The Breakthroughs